A critique of available scales and presentation of the non‐human primate dyskinesia rating scale
Identifieur interne : 000834 ( Istex/Corpus ); précédent : 000833; suivant : 000835A critique of available scales and presentation of the non‐human primate dyskinesia rating scale
Auteurs : Susan H. Fox ; Tom H. Johnston ; Qin Li ; Jonathan Brotchie ; Erwan BezardSource :
- Movement Disorders [ 0885-3185 ] ; 2012-09-15.
English descriptors
Abstract
Levodopa‐induced dyskinesia (LID) is a major limitation of long‐term management of Parkinson's disease. The roadblocks that have hindered the development of new treatments for levodopa‐induced dyskinesia were discussed at a meeting organized by the Michael J. Fox Foundation for Parkinson's research (New York, NY, March 2011). Among these, the lack of consensus methodology and clinical applicability for eliciting and rating LID in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)–treated monkeys was highlighted as a particular concern. Here we present an update on the practical use of rating scales for evaluating LID in MPTP‐lesioned primate models of PD, with a focus on macaques, and present specifics on the Non‐Human Primate Dyskinesia Rating Scale. © 2012 Movement Disorder Society
Url:
DOI: 10.1002/mds.25133
Links to Exploration step
ISTEX:CFED906103BCB1059D674899A2FEDFE0BE385AF5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A critique of available scales and presentation of the non‐human primate dyskinesia rating scale</title>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation><mods:affiliation>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Division of Neurology, University of Toronto, and University Health Network, Movement Disorder Clinic, Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Susan H. Fox, CNRS UMR 5293, IMN, Université Bordeaux Segalen, 146 rue Léo Saignat, 33076 Bordeaux cedex, FranceErwan Bezard, Movement Disorder Clinic, McL 7‐421, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON, Canada, M5T 2S8</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
<affiliation><mods:affiliation>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Li, Qin" sort="Li, Qin" uniqKey="Li Q" first="Qin" last="Li">Qin Li</name>
<affiliation><mods:affiliation>Institute of Lab Animal Sciences, China Academy of Medical Sciences, Beijing, China</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan" sort="Brotchie, Jonathan" uniqKey="Brotchie J" first="Jonathan" last="Brotchie">Jonathan Brotchie</name>
<affiliation><mods:affiliation>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name>
<affiliation><mods:affiliation>Institute of Lab Animal Sciences, China Academy of Medical Sciences, Beijing, China</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Susan H. Fox, CNRS UMR 5293, IMN, Université Bordeaux Segalen, 146 rue Léo Saignat, 33076 Bordeaux cedex, FranceErwan Bezard, Movement Disorder Clinic, McL 7‐421, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON, Canada, M5T 2S8</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:CFED906103BCB1059D674899A2FEDFE0BE385AF5</idno>
<date when="2012" year="2012">2012</date>
<idno type="doi">10.1002/mds.25133</idno>
<idno type="url">https://api.istex.fr/document/CFED906103BCB1059D674899A2FEDFE0BE385AF5/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000834</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000834</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A critique of available scales and presentation of the non‐human primate dyskinesia rating scale</title>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation><mods:affiliation>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Division of Neurology, University of Toronto, and University Health Network, Movement Disorder Clinic, Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Susan H. Fox, CNRS UMR 5293, IMN, Université Bordeaux Segalen, 146 rue Léo Saignat, 33076 Bordeaux cedex, FranceErwan Bezard, Movement Disorder Clinic, McL 7‐421, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON, Canada, M5T 2S8</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
<affiliation><mods:affiliation>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Li, Qin" sort="Li, Qin" uniqKey="Li Q" first="Qin" last="Li">Qin Li</name>
<affiliation><mods:affiliation>Institute of Lab Animal Sciences, China Academy of Medical Sciences, Beijing, China</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan" sort="Brotchie, Jonathan" uniqKey="Brotchie J" first="Jonathan" last="Brotchie">Jonathan Brotchie</name>
<affiliation><mods:affiliation>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name>
<affiliation><mods:affiliation>Institute of Lab Animal Sciences, China Academy of Medical Sciences, Beijing, China</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Susan H. Fox, CNRS UMR 5293, IMN, Université Bordeaux Segalen, 146 rue Léo Saignat, 33076 Bordeaux cedex, FranceErwan Bezard, Movement Disorder Clinic, McL 7‐421, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON, Canada, M5T 2S8</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2012-09-15">2012-09-15</date>
<biblScope unit="volume">27</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1373">1373</biblScope>
<biblScope unit="page" to="1378">1378</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">CFED906103BCB1059D674899A2FEDFE0BE385AF5</idno>
<idno type="DOI">10.1002/mds.25133</idno>
<idno type="ArticleID">MDS25133</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>L‐dopa</term>
<term>MPTP</term>
<term>NHPDysR</term>
<term>Parkinson's disease</term>
<term>chorea</term>
<term>dystonia</term>
<term>macaque</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Levodopa‐induced dyskinesia (LID) is a major limitation of long‐term management of Parkinson's disease. The roadblocks that have hindered the development of new treatments for levodopa‐induced dyskinesia were discussed at a meeting organized by the Michael J. Fox Foundation for Parkinson's research (New York, NY, March 2011). Among these, the lack of consensus methodology and clinical applicability for eliciting and rating LID in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)–treated monkeys was highlighted as a particular concern. Here we present an update on the practical use of rating scales for evaluating LID in MPTP‐lesioned primate models of PD, with a focus on macaques, and present specifics on the Non‐Human Primate Dyskinesia Rating Scale. © 2012 Movement Disorder Society</div>
</front>
</TEI>
<istex><corpusName>wiley</corpusName>
<author><json:item><name>Susan H. Fox MD, PhD</name>
<affiliations><json:string>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</json:string>
<json:string>Division of Neurology, University of Toronto, and University Health Network, Movement Disorder Clinic, Toronto Western Hospital, Toronto, Ontario, Canada</json:string>
<json:string>Susan H. Fox, CNRS UMR 5293, IMN, Université Bordeaux Segalen, 146 rue Léo Saignat, 33076 Bordeaux cedex, FranceErwan Bezard, Movement Disorder Clinic, McL 7‐421, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON, Canada, M5T 2S8</json:string>
</affiliations>
</json:item>
<json:item><name>Tom H. Johnston PhD</name>
<affiliations><json:string>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</json:string>
</affiliations>
</json:item>
<json:item><name>Qin Li PhD</name>
<affiliations><json:string>Institute of Lab Animal Sciences, China Academy of Medical Sciences, Beijing, China</json:string>
</affiliations>
</json:item>
<json:item><name>Jonathan Brotchie PhD</name>
<affiliations><json:string>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</json:string>
</affiliations>
</json:item>
<json:item><name>Erwan Bezard PhD</name>
<affiliations><json:string>Institute of Lab Animal Sciences, China Academy of Medical Sciences, Beijing, China</json:string>
<json:string>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France</json:string>
<json:string>CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France</json:string>
<json:string>Susan H. Fox, CNRS UMR 5293, IMN, Université Bordeaux Segalen, 146 rue Léo Saignat, 33076 Bordeaux cedex, FranceErwan Bezard, Movement Disorder Clinic, McL 7‐421, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON, Canada, M5T 2S8</json:string>
</affiliations>
</json:item>
</author>
<subject><json:item><lang><json:string>eng</json:string>
</lang>
<value>Parkinson's disease</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>L‐dopa</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>macaque</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>MPTP</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>chorea</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>dystonia</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>NHPDysR</value>
</json:item>
</subject>
<articleId><json:string>MDS25133</json:string>
</articleId>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>reviewArticle</json:string>
</originalGenre>
<abstract>Levodopa‐induced dyskinesia (LID) is a major limitation of long‐term management of Parkinson's disease. The roadblocks that have hindered the development of new treatments for levodopa‐induced dyskinesia were discussed at a meeting organized by the Michael J. Fox Foundation for Parkinson's research (New York, NY, March 2011). Among these, the lack of consensus methodology and clinical applicability for eliciting and rating LID in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)–treated monkeys was highlighted as a particular concern. Here we present an update on the practical use of rating scales for evaluating LID in MPTP‐lesioned primate models of PD, with a focus on macaques, and present specifics on the Non‐Human Primate Dyskinesia Rating Scale. © 2012 Movement Disorder Society</abstract>
<qualityIndicators><score>4.776</score>
<pdfVersion>1.4</pdfVersion>
<pdfPageSize>612 x 810 pts</pdfPageSize>
<refBibsNative>true</refBibsNative>
<abstractCharCount>795</abstractCharCount>
<pdfWordCount>2932</pdfWordCount>
<pdfCharCount>19983</pdfCharCount>
<pdfPageCount>6</pdfPageCount>
<abstractWordCount>112</abstractWordCount>
</qualityIndicators>
<title>A critique of available scales and presentation of the non‐human primate dyskinesia rating scale</title>
<refBibs><json:item><author><json:item><name>SH Fox</name>
</json:item>
<json:item><name>R Katzenschlager</name>
</json:item>
<json:item><name>SY Lim</name>
</json:item>
</author>
<host><volume>26</volume>
<pages><last>41</last>
<first>2</first>
</pages>
<issue>Suppl 3</issue>
<author></author>
<title>Mov Disord.</title>
</host>
<title>The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease</title>
</json:item>
<json:item><author><json:item><name>R Pahwa</name>
</json:item>
<json:item><name>SA Factor</name>
</json:item>
<json:item><name>KE Lyons</name>
</json:item>
</author>
<host><volume>66</volume>
<pages><last>995</last>
<first>983</first>
</pages>
<author></author>
<title>Neurology.</title>
</host>
<title>Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence‐based review): report of the Quality Standards Subcommittee of the American Academy of Neurology</title>
</json:item>
<json:item><author><json:item><name>P Jenner</name>
</json:item>
</author>
<host><volume>9</volume>
<pages><last>677</last>
<first>665</first>
</pages>
<author></author>
<title>Nat Rev Neurosci.</title>
</host>
<title>Molecular mechanisms of L‐DOPA‐induced dyskinesia</title>
</json:item>
<json:item><author><json:item><name>WG Meissner</name>
</json:item>
<json:item><name>M Frasier</name>
</json:item>
<json:item><name>T Gasser</name>
</json:item>
</author>
<host><volume>10</volume>
<pages><last>393</last>
<first>377</first>
</pages>
<author></author>
<title>Nat Rev Drug Discov.</title>
</host>
<title>Priorities in Parkinson's disease research</title>
</json:item>
<json:item><author><json:item><name>S Boyce</name>
</json:item>
<json:item><name>NM Rupniak</name>
</json:item>
<json:item><name>MJ Steventon</name>
</json:item>
<json:item><name>SD Iversen</name>
</json:item>
</author>
<host><volume>102</volume>
<pages><last>27</last>
<first>21</first>
</pages>
<author></author>
<title>Psychopharmacology (Berl).</title>
</host>
<title>Characterisation of dyskinesias induced by L‐dopa in MPTP‐treated squirrel monkeys</title>
</json:item>
<json:item><author><json:item><name>B Gomez‐Mancilla</name>
</json:item>
<json:item><name>PJ Bédard</name>
</json:item>
</author>
<host><volume>16</volume>
<pages><last>427</last>
<first>418</first>
</pages>
<author></author>
<title>Clin Neuropharmacol.</title>
</host>
<title>Effect of nondopaminergic drugs on L‐dopa‐induced dyskinesias in MPTP‐treated monkeys</title>
</json:item>
<json:item><author><json:item><name>PJ Blanchet</name>
</json:item>
<json:item><name>F Calon</name>
</json:item>
<json:item><name>JC Martel</name>
</json:item>
</author>
<host><volume>272</volume>
<pages><last>859</last>
<first>854</first>
</pages>
<author></author>
<title>J Pharmacol Exp Ther.</title>
</host>
<title>Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U‐91356A) in MPTP‐exposed monkeys</title>
</json:item>
<json:item><host><author></author>
<title>In preparation, developed by Kathy Steece‐Collier, PhD (Michigan State University), Jeffrey H. Kordower, PhD, and Kathleen Shannon, MD (Rush University).</title>
</host>
</json:item>
<json:item><author><json:item><name>RK Pearce</name>
</json:item>
<json:item><name>M Jackson</name>
</json:item>
<json:item><name>L Smith</name>
</json:item>
<json:item><name>P Jenner</name>
</json:item>
<json:item><name>CD Marsden</name>
</json:item>
</author>
<host><volume>10</volume>
<pages><last>740</last>
<first>731</first>
</pages>
<author></author>
<title>Mov Disord.</title>
</host>
<title>Chronic L‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐ phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix Jacchus)</title>
</json:item>
<json:item><author><json:item><name>B Henry</name>
</json:item>
<json:item><name>SH Fox</name>
</json:item>
<json:item><name>D Peggs</name>
</json:item>
<json:item><name>AR Crossman</name>
</json:item>
<json:item><name>JM Brotchie</name>
</json:item>
</author>
<host><volume>14</volume>
<pages><last>753</last>
<first>744</first>
</pages>
<author></author>
<title>Mov Disord.</title>
</host>
<title>The alpha2‐adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti‐parkinsonian actions of L‐dopa in the MPTP‐lesioned primate model of Parkinson's disease</title>
</json:item>
<json:item><author><json:item><name>T Boraud</name>
</json:item>
<json:item><name>E Bezard</name>
</json:item>
<json:item><name>B Bioulac</name>
</json:item>
<json:item><name>CE Gross</name>
</json:item>
</author>
<host><volume>124</volume>
<pages><last>557</last>
<first>546</first>
</pages>
<author></author>
<title>Brain.</title>
</host>
<title>Dopamine agonist‐induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP‐treated monkey</title>
</json:item>
<json:item><author><json:item><name>TH Johnston</name>
</json:item>
<json:item><name>SH Fox</name>
</json:item>
<json:item><name>MJ Piggott</name>
</json:item>
<json:item><name>JM Savola</name>
</json:item>
<json:item><name>JM Brotchie</name>
</json:item>
</author>
<host><volume>25</volume>
<pages><last>2093</last>
<first>2084</first>
</pages>
<author></author>
<title>Mov Disord.</title>
</host>
<title>The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates</title>
</json:item>
<json:item><author><json:item><name>GM Petzinger</name>
</json:item>
<json:item><name>M Quik</name>
</json:item>
<json:item><name>E Ivashina</name>
</json:item>
</author>
<host><volume>16</volume>
<pages><last>207</last>
<first>202</first>
</pages>
<author></author>
<title>Mov Disord.</title>
</host>
<title>Reliability and validity of a new global dyskinesia rating scale in the MPTP‐lesioned non‐human primate</title>
</json:item>
<json:item><author><json:item><name>LC Tan</name>
</json:item>
<json:item><name>PH Protell</name>
</json:item>
<json:item><name>JW Langston</name>
</json:item>
<json:item><name>DM Togasaki</name>
</json:item>
</author>
<host><volume>17</volume>
<pages><last>909</last>
<first>902</first>
</pages>
<author></author>
<title>Mov Disord.</title>
</host>
<title>The hyperkinetic abnormal movements scale: a tool for measuring levodopa‐induced abnormal movements in squirrel monkeys</title>
</json:item>
<json:item><author><json:item><name>JR Taylor</name>
</json:item>
<json:item><name>JD Elsworth</name>
</json:item>
<json:item><name>RH Roth</name>
</json:item>
<json:item><name>TJ Collier</name>
</json:item>
<json:item><name>JR Sladek Jr</name>
</json:item>
<json:item><name>DE Redmond Jr</name>
</json:item>
</author>
<host><volume>82</volume>
<pages><last>559</last>
<first>543</first>
</pages>
<author></author>
<title>Prog Brain Res.</title>
</host>
<title>Improvements in MPTP‐induced object retrieval deficits and behavioral deficits after fetal nigral grafting in monkeys</title>
</json:item>
<json:item><author><json:item><name>C Colosimo</name>
</json:item>
<json:item><name>P Martínez‐Martín</name>
</json:item>
<json:item><name>G Fabbrini</name>
</json:item>
</author>
<host><volume>25</volume>
<pages><last>1142</last>
<first>1131</first>
</pages>
<author></author>
<title>Mov Disord.</title>
</host>
<title>Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations</title>
</json:item>
<json:item><author><json:item><name>JM Brotchie</name>
</json:item>
<json:item><name>SH Fox</name>
</json:item>
</author>
<host><volume>14</volume>
<pages><last>47</last>
<first>40</first>
</pages>
<issue>Suppl 1</issue>
<author></author>
<title>Mov Disord.</title>
</host>
<title>Quantitative assessment of dyskinesias in subhuman primates</title>
</json:item>
</refBibs>
<genre><json:string>review-article</json:string>
</genre>
<host><volume>27</volume>
<publisherId><json:string>MDS</json:string>
</publisherId>
<pages><total>6</total>
<last>1378</last>
<first>1373</first>
</pages>
<issn><json:string>0885-3185</json:string>
</issn>
<issue>11</issue>
<subject><json:item><value>Review</value>
</json:item>
</subject>
<genre><json:string>journal</json:string>
</genre>
<language><json:string>unknown</json:string>
</language>
<eissn><json:string>1531-8257</json:string>
</eissn>
<title>Movement Disorders</title>
<doi><json:string>10.1002/(ISSN)1531-8257</json:string>
</doi>
</host>
<categories><wos><json:string>science</json:string>
<json:string>clinical neurology</json:string>
</wos>
<scienceMetrix><json:string>health sciences</json:string>
<json:string>clinical medicine</json:string>
<json:string>neurology & neurosurgery</json:string>
</scienceMetrix>
</categories>
<publicationDate>2012</publicationDate>
<copyrightDate>2012</copyrightDate>
<doi><json:string>10.1002/mds.25133</json:string>
</doi>
<id>CFED906103BCB1059D674899A2FEDFE0BE385AF5</id>
<score>0.101056546</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/document/CFED906103BCB1059D674899A2FEDFE0BE385AF5/fulltext/pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/document/CFED906103BCB1059D674899A2FEDFE0BE385AF5/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/CFED906103BCB1059D674899A2FEDFE0BE385AF5/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">A critique of available scales and presentation of the non‐human primate dyskinesia rating scale</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<availability><p>Copyright © 2012 Movement Disorder Society</p>
</availability>
<date>2012</date>
</publicationStmt>
<notesStmt><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note>
<note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note>
</notesStmt>
<sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">A critique of available scales and presentation of the non‐human primate dyskinesia rating scale</title>
<author xml:id="author-1"><persName><forename type="first">Susan H.</forename>
<surname>Fox</surname>
</persName>
<roleName type="degree">MD, PhD</roleName>
<affiliation>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</affiliation>
<affiliation>Division of Neurology, University of Toronto, and University Health Network, Movement Disorder Clinic, Toronto Western Hospital, Toronto, Ontario, Canada</affiliation>
<affiliation>Susan H. Fox, CNRS UMR 5293, IMN, Université Bordeaux Segalen, 146 rue Léo Saignat, 33076 Bordeaux cedex, FranceErwan Bezard, Movement Disorder Clinic, McL 7‐421, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON, Canada, M5T 2S8</affiliation>
</author>
<author xml:id="author-2"><persName><forename type="first">Tom H.</forename>
<surname>Johnston</surname>
</persName>
<roleName type="degree">PhD</roleName>
<affiliation>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</affiliation>
</author>
<author xml:id="author-3"><persName><forename type="first">Qin</forename>
<surname>Li</surname>
</persName>
<roleName type="degree">PhD</roleName>
<affiliation>Institute of Lab Animal Sciences, China Academy of Medical Sciences, Beijing, China</affiliation>
</author>
<author xml:id="author-4"><persName><forename type="first">Jonathan</forename>
<surname>Brotchie</surname>
</persName>
<roleName type="degree">PhD</roleName>
<affiliation>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</affiliation>
</author>
<author xml:id="author-5"><persName><forename type="first">Erwan</forename>
<surname>Bezard</surname>
</persName>
<roleName type="degree">PhD</roleName>
<affiliation>Institute of Lab Animal Sciences, China Academy of Medical Sciences, Beijing, China</affiliation>
<affiliation>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France</affiliation>
<affiliation>CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France</affiliation>
<affiliation>Susan H. Fox, CNRS UMR 5293, IMN, Université Bordeaux Segalen, 146 rue Léo Saignat, 33076 Bordeaux cedex, FranceErwan Bezard, Movement Disorder Clinic, McL 7‐421, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON, Canada, M5T 2S8</affiliation>
</author>
</analytic>
<monogr><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="pISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<idno type="DOI">10.1002/(ISSN)1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2012-09-15"></date>
<biblScope unit="volume">27</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1373">1373</biblScope>
<biblScope unit="page" to="1378">1378</biblScope>
</imprint>
</monogr>
<idno type="istex">CFED906103BCB1059D674899A2FEDFE0BE385AF5</idno>
<idno type="DOI">10.1002/mds.25133</idno>
<idno type="ArticleID">MDS25133</idno>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><creation><date>2012</date>
</creation>
<langUsage><language ident="en">en</language>
</langUsage>
<abstract xml:lang="en"><p>Levodopa‐induced dyskinesia (LID) is a major limitation of long‐term management of Parkinson's disease. The roadblocks that have hindered the development of new treatments for levodopa‐induced dyskinesia were discussed at a meeting organized by the Michael J. Fox Foundation for Parkinson's research (New York, NY, March 2011). Among these, the lack of consensus methodology and clinical applicability for eliciting and rating LID in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)–treated monkeys was highlighted as a particular concern. Here we present an update on the practical use of rating scales for evaluating LID in MPTP‐lesioned primate models of PD, with a focus on macaques, and present specifics on the Non‐Human Primate Dyskinesia Rating Scale. © 2012 Movement Disorder Society</p>
</abstract>
<textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head>
<item><term>Parkinson's disease</term>
</item>
<item><term>L‐dopa</term>
</item>
<item><term>macaque</term>
</item>
<item><term>MPTP</term>
</item>
<item><term>chorea</term>
</item>
<item><term>dystonia</term>
</item>
<item><term>NHPDysR</term>
</item>
</list>
</keywords>
</textClass>
<textClass><keywords scheme="Journal Subject"><list><head>article-category</head>
<item><term>Review</term>
</item>
</list>
</keywords>
</textClass>
</profileDesc>
<revisionDesc><change when="2012-04-18">Received</change>
<change when="2012-07-12">Registration</change>
<change when="2012-09-15">Published</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/document/CFED906103BCB1059D674899A2FEDFE0BE385AF5/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName>
<publisherLoc>Hoboken</publisherLoc>
</publisherInfo>
<doi registered="yes">10.1002/(ISSN)1531-8257</doi>
<issn type="print">0885-3185</issn>
<issn type="electronic">1531-8257</issn>
<idGroup><id type="product" value="MDS"></id>
</idGroup>
<titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title>
<title type="short">Mov. Disord.</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="110"><doi origin="wiley" registered="yes">10.1002/mds.v27.11</doi>
<numberingGroup><numbering type="journalVolume" number="27">27</numbering>
<numbering type="journalIssue">11</numbering>
</numberingGroup>
<coverDate startDate="2012-09-15">15 September 2012</coverDate>
</publicationMeta>
<publicationMeta level="unit" type="reviewArticle" position="130" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.25133</doi>
<idGroup><id type="unit" value="MDS25133"></id>
</idGroup>
<countGroup><count type="pageTotal" number="6"></count>
</countGroup>
<titleGroup><title type="articleCategory">Review</title>
<title type="tocHeading1">Reviews</title>
</titleGroup>
<copyright ownership="thirdParty">Copyright © 2012 Movement Disorder Society</copyright>
<eventGroup><event type="manuscriptReceived" date="2012-04-18"></event>
<event type="manuscriptRevised" date="2012-06-26"></event>
<event type="manuscriptAccepted" date="2012-07-12"></event>
<event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.1.9 mode:FullText" date="2013-01-21"></event>
<event type="publishedOnlineEarlyUnpaginated" date="2012-09-13"></event>
<event type="publishedOnlineFinalForm" date="2012-09-21"></event>
<event type="firstOnline" date="2012-09-13"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.3.4 mode:FullText" date="2015-02-24"></event>
</eventGroup>
<numberingGroup><numbering type="pageFirst">1373</numbering>
<numbering type="pageLast">1378</numbering>
</numberingGroup>
<correspondenceTo><lineatedText><line>Susan H. Fox, CNRS UMR 5293, IMN, Université Bordeaux Segalen, 146 rue Léo Saignat, 33076 Bordeaux cedex, France</line>
<line>Erwan Bezard, Movement Disorder Clinic, McL 7‐421, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON, Canada, M5T 2S8</line>
</lineatedText>
</correspondenceTo>
<linkGroup><link type="toTypesetVersion" href="file:MDS.MDS25133.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta><countGroup><count type="figureTotal" number="0"></count>
<count type="tableTotal" number="1"></count>
<count type="referenceTotal" number="17"></count>
<count type="wordTotal" number="4034"></count>
</countGroup>
<titleGroup><title type="main" xml:lang="en">A critique of available scales and presentation of the non‐human primate dyskinesia rating scale<link href="#fn1"></link>
<link href="#fn2"></link>
</title>
<title type="short" xml:lang="en">Dyskinesia Rating in Monkeys</title>
</titleGroup>
<creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Susan H.</givenNames>
<familyName>Fox</familyName>
<degrees>MD, PhD</degrees>
</personName>
<contactDetails><email>sfox@uhnresearch.ca</email>
</contactDetails>
</creator>
<creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Tom H.</givenNames>
<familyName>Johnston</familyName>
<degrees>PhD</degrees>
</personName>
</creator>
<creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Qin</givenNames>
<familyName>Li</familyName>
<degrees>PhD</degrees>
</personName>
</creator>
<creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Jonathan</givenNames>
<familyName>Brotchie</familyName>
<degrees>PhD</degrees>
</personName>
</creator>
<creator xml:id="au5" creatorRole="author" affiliationRef="#af3 #af4 #af5" corresponding="yes"><personName><givenNames>Erwan</givenNames>
<familyName>Bezard</familyName>
<degrees>PhD</degrees>
</personName>
<contactDetails><email normalForm="erwan.bezard@u-bordeaux2.fr">erwan.bezard@u‐bordeaux2.fr</email>
</contactDetails>
</creator>
</creators>
<affiliationGroup><affiliation xml:id="af1" countryCode="CA" type="organization"><unparsedAffiliation>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af2" countryCode="CA" type="organization"><unparsedAffiliation>Division of Neurology, University of Toronto, and University Health Network, Movement Disorder Clinic, Toronto Western Hospital, Toronto, Ontario, Canada</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af3" countryCode="CN" type="organization"><unparsedAffiliation>Institute of Lab Animal Sciences, China Academy of Medical Sciences, Beijing, China</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af4" countryCode="FR" type="organization"><unparsedAffiliation>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af5" countryCode="FR" type="organization"><unparsedAffiliation>CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France</unparsedAffiliation>
</affiliation>
</affiliationGroup>
<keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword>
<keyword xml:id="kwd2"><sc>L</sc>
‐dopa</keyword>
<keyword xml:id="kwd3">macaque</keyword>
<keyword xml:id="kwd4">MPTP</keyword>
<keyword xml:id="kwd5">chorea</keyword>
<keyword xml:id="kwd6">dystonia</keyword>
<keyword xml:id="kwd7">NHPDysR</keyword>
</keywordGroup>
<supportingInformation><p> Supporting information may be found in the online version of the article. </p>
<supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds25133:MDS_25133_sm_SuppMovPart1"></mediaResource>
<caption>Supporting Movie Part I</caption>
</supportingInfoItem>
<supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds25133:MDS_25133_sm_SuppMovPart2"></mediaResource>
<caption>Supporting Movie Part II</caption>
</supportingInfoItem>
</supportingInformation>
<abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title>
<p>Levodopa‐induced dyskinesia (LID) is a major limitation of long‐term management of Parkinson's disease. The roadblocks that have hindered the development of new treatments for levodopa‐induced dyskinesia were discussed at a meeting organized by the Michael J. Fox Foundation for Parkinson's research (New York, NY, March 2011). Among these, the lack of consensus methodology and clinical applicability for eliciting and rating LID in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)–treated monkeys was highlighted as a particular concern. Here we present an update on the practical use of rating scales for evaluating LID in MPTP‐lesioned primate models of PD, with a focus on macaques, and present specifics on the Non‐Human Primate Dyskinesia Rating Scale. © 2012 Movement Disorder Society</p>
</abstract>
</abstractGroup>
</contentMeta>
<noteGroup><note xml:id="fn1"><p><b>Relevant conflicts of interest/financial disclosures:</b>
Nothing to report.</p>
</note>
<note xml:id="fn2"><p>Full financial disclosures and author roles may be found in the online version of this article.</p>
</note>
</noteGroup>
</header>
</component>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo lang="en"><title>A critique of available scales and presentation of the non‐human primate dyskinesia rating scale</title>
</titleInfo>
<titleInfo type="abbreviated" lang="en"><title>Dyskinesia Rating in Monkeys</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en"><title>A critique of available scales and presentation of the non‐human primate dyskinesia rating scale</title>
</titleInfo>
<name type="personal"><namePart type="given">Susan H.</namePart>
<namePart type="family">Fox</namePart>
<namePart type="termsOfAddress">MD, PhD</namePart>
<affiliation>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</affiliation>
<affiliation>Division of Neurology, University of Toronto, and University Health Network, Movement Disorder Clinic, Toronto Western Hospital, Toronto, Ontario, Canada</affiliation>
<affiliation>Susan H. Fox, CNRS UMR 5293, IMN, Université Bordeaux Segalen, 146 rue Léo Saignat, 33076 Bordeaux cedex, FranceErwan Bezard, Movement Disorder Clinic, McL 7‐421, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON, Canada, M5T 2S8</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Tom H.</namePart>
<namePart type="family">Johnston</namePart>
<namePart type="termsOfAddress">PhD</namePart>
<affiliation>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Qin</namePart>
<namePart type="family">Li</namePart>
<namePart type="termsOfAddress">PhD</namePart>
<affiliation>Institute of Lab Animal Sciences, China Academy of Medical Sciences, Beijing, China</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Jonathan</namePart>
<namePart type="family">Brotchie</namePart>
<namePart type="termsOfAddress">PhD</namePart>
<affiliation>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Erwan</namePart>
<namePart type="family">Bezard</namePart>
<namePart type="termsOfAddress">PhD</namePart>
<affiliation>Institute of Lab Animal Sciences, China Academy of Medical Sciences, Beijing, China</affiliation>
<affiliation>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France</affiliation>
<affiliation>CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France</affiliation>
<affiliation>Susan H. Fox, CNRS UMR 5293, IMN, Université Bordeaux Segalen, 146 rue Léo Saignat, 33076 Bordeaux cedex, FranceErwan Bezard, Movement Disorder Clinic, McL 7‐421, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON, Canada, M5T 2S8</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="review-article" displayLabel="reviewArticle"></genre>
<originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<place><placeTerm type="text">Hoboken</placeTerm>
</place>
<dateIssued encoding="w3cdtf">2012-09-15</dateIssued>
<dateCaptured encoding="w3cdtf">2012-04-18</dateCaptured>
<dateValid encoding="w3cdtf">2012-07-12</dateValid>
<copyrightDate encoding="w3cdtf">2012</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription><internetMediaType>text/html</internetMediaType>
<extent unit="tables">1</extent>
<extent unit="references">17</extent>
<extent unit="words">4034</extent>
</physicalDescription>
<abstract lang="en">Levodopa‐induced dyskinesia (LID) is a major limitation of long‐term management of Parkinson's disease. The roadblocks that have hindered the development of new treatments for levodopa‐induced dyskinesia were discussed at a meeting organized by the Michael J. Fox Foundation for Parkinson's research (New York, NY, March 2011). Among these, the lack of consensus methodology and clinical applicability for eliciting and rating LID in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)–treated monkeys was highlighted as a particular concern. Here we present an update on the practical use of rating scales for evaluating LID in MPTP‐lesioned primate models of PD, with a focus on macaques, and present specifics on the Non‐Human Primate Dyskinesia Rating Scale. © 2012 Movement Disorder Society</abstract>
<note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note>
<note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note>
<subject lang="en"><genre>keywords</genre>
<topic>Parkinson's disease</topic>
<topic>L‐dopa</topic>
<topic>macaque</topic>
<topic>MPTP</topic>
<topic>chorea</topic>
<topic>dystonia</topic>
<topic>NHPDysR</topic>
</subject>
<relatedItem type="host"><titleInfo><title>Movement Disorders</title>
</titleInfo>
<titleInfo type="abbreviated"><title>Mov. Disord.</title>
</titleInfo>
<genre type="journal">journal</genre>
<note type="content"> Supporting information may be found in the online version of the article.Supporting Info Item: Supporting Movie Part I - Supporting Movie Part II - </note>
<subject><genre>article-category</genre>
<topic>Review</topic>
</subject>
<identifier type="ISSN">0885-3185</identifier>
<identifier type="eISSN">1531-8257</identifier>
<identifier type="DOI">10.1002/(ISSN)1531-8257</identifier>
<identifier type="PublisherID">MDS</identifier>
<part><date>2012</date>
<detail type="volume"><caption>vol.</caption>
<number>27</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>11</number>
</detail>
<extent unit="pages"><start>1373</start>
<end>1378</end>
<total>6</total>
</extent>
</part>
</relatedItem>
<identifier type="istex">CFED906103BCB1059D674899A2FEDFE0BE385AF5</identifier>
<identifier type="DOI">10.1002/mds.25133</identifier>
<identifier type="ArticleID">MDS25133</identifier>
<accessCondition type="use and reproduction" contentType="copyright">Copyright © 2012 Movement Disorder Society</accessCondition>
<recordInfo><recordContentSource>WILEY</recordContentSource>
<recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin>
</recordInfo>
</mods>
</metadata>
<serie></serie>
</istex>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000834 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000834 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Istex |étape= Corpus |type= RBID |clé= ISTEX:CFED906103BCB1059D674899A2FEDFE0BE385AF5 |texte= A critique of available scales and presentation of the non‐human primate dyskinesia rating scale }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |